Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
06:17am, Thursday, 23'rd Jan 2025
Eli Lilly (LLY 1.57%) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.
MED Focused on GLP-1 Solutions Amid Customer Acquisition Challenges
10:46am, Wednesday, 22'nd Jan 2025
With a strategic focus on innovation and a robust operational framework, Medifast is well-placed for growth in the weight loss and GLP-1 medication space.
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares Rise
09:55am, Wednesday, 22'nd Jan 2025
Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney diseases as well certain brain ailments.
ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose (SAD) study of patients with obesity, supportin
Hims & Hers Health: The Market Is Likely Wrong
03:14pm, Sunday, 19'th Jan 2025
Hims & Hers Health is undervalued despite impressive growth, with analysts overly focused on compounded GLP-1s and potential FDA restrictions. BoA's negative outlook contrasts with Hims' projected 90%
GLP-1s and Brian Thompson's killing loom large at top health-care conference
08:00am, Saturday, 18'th Jan 2025
Thousands of health-care executives descended on JPMorgan's annual health-care conference in San Francisco this week. The conference took place a month after UnitedHealthcare CEO Brian Thompson was fa
Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
06:05am, Saturday, 18'th Jan 2025
GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (LLY -4.21%) Mounjaro skyrocketing over the past year. However, Eli Lilly recentl
Dr. Kavita Patel talks impact of GLP-1 price negotiations
06:45pm, Friday, 17'th Jan 2025
Dr. Kavita Patel joins 'Fast Money' to talk what is next for GLP-1 drug makers.
New Year's Resolutions: Lose Weight & Allocate to GLP-1 ETFs
07:05am, Friday, 17'th Jan 2025
For many of us, a new year often means a new chance to start fresh in our battle with weight. Thanks to interesting ETF product development, especially in the past year, it could also mean a chance to
Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval
09:20am, Wednesday, 15'th Jan 2025
Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria B
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?
09:06am, Wednesday, 15'th Jan 2025
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024.
Global Partners Announces Cash Distribution on Series B Preferred Units
08:30am, Monday, 13'th Jan 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that the Board of Directors (the “Board”) of its general partner, Global GP LLC, has declare
Tiziana Life Sciences' foralumab reduces side effects of discontinuing GLP-1 agonists
10:09am, Friday, 10'th Jan 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its intranasal anti-CD3 monoclonal antibody, foralumab, has demonstrated the ability to mitigate the side effects associated with the discontinua
GLP-1 makers could be under pressure in 2025
07:29pm, Monday, 06'th Jan 2025
Jared Holz, Mizuho, joins 'Fast Money' to talk what is next for the obesity drug makers in 2025.
Cramer's Mad Dash: Cornell report on GLP-1s shows decrease in consumption of savory snacks
11:19am, Friday, 03'rd Jan 2025
CNBC's Jim Cramer reports on a study from Cornell and its impact on the stock market.
